Charlie Whelan

• 
  www.mysanantonio.com/business/local/KCI_posts20_percent - [Cached Version]
  Published on: 10/22/2009    Last Visited: 10/22/2009  

  "Both of those are going to be good," said Charlie Whelan, a medical device analyst for Frost & Sullivan.
  ...
  "It's not good when you have a billion-dollar company that's about the same one year as it was 12 months prior," Whelan said.

• 
  www.smartcardstrends.com/det_atc.php?idu=10213&main=255 - [Cached Version]
  Published on: 9/30/2009    Last Visited: 11/3/2009  

  "In most cases, these companies see an ability to leverage their strengths to tap into a market with strong fundamentals - an aging population, consistent growth and the ability to reward innovation," explains Charlie Whelan, Director of Healthcare Consulting for Frost & Sullivan.
  ...
  "Companies with a fresh, outside perspective will be invaluable to improving healthcare delivery and producing the next generation of medical technology," adds Whelan.

• 
  www.devicelink.com/mddi/archive/09/09/006.html - [Cached Version]
  Published on: 9/23/2009    Last Visited: 9/23/2009  

  Charlie Whelan
  ...
  Charlie Whelan is director of consulting, healthcare and lifesciences, for Frost & Sullivan. He can be reached via e-mail at cwhelan@frost.com.

• 
  www.mysanantonio.com/business/Toyota_med_center_provide - [Cached Version]
  Published on: 11/23/2008    Last Visited: 11/24/2008  

  For small and midsized employers, the cost is prohibitive, said Charlie Whelan, director of health care consulting for market researcher Frost & Sullivan.
  
  "Everyone knows that preventative care is the way our health care system should be headed," Whelan said.

• 
  www.executivehm.com/article/Third-Time-Lucky/ - [Cached Version]
  Last Visited: 10/6/2009  

  According to Charlie Whelan, Director of Consulting in the Healthcare Practice at analysts Frost & Sullivan, Obama has learned from Clinton's mistakes.
  ...
  Says Frost & Sullivan's Charlie Whelan: "Other people have criticized where some of the money is coming from, and whether it's changing the amount of tax deductions that rich people and corporations are able to take or cuts to reimbursement to Medicare managed funds.

• 
  www.frost.com/prod/servlet/ebroadcast.pag?eventid=86499 - [Cached Version]
  Published on: 12/23/2006    Last Visited: 12/23/2006  

  Charlie Whelan, Consulting Manager, Healthcare, Frost & Sullivan
  
  Charlie will discuss the difference between the short-term fix of traditional adherence and loyalty programs and where future...

• 
  www.devicelink.com/mddi/archive/09/09/018.html - [Cached Version]
  Published on: 9/23/2009    Last Visited: 9/23/2009  

  Charlie Whelan is a director of Frost & Sullivan's North American healthcare consulting practice (San Antonio). Focusing on the medical device and patient monitoring sectors, Whelan has partnered with such companies as Medtronic, 3M Healthcare, and Johnson & Johnson. Reach him at cwhelan@frost.com.
  
  Alpaslan Yaman , PhD, is a principal consultant for Biotech, Pharma & Device Consulting LLC (Parsippany, NJ). He is a certified black belt and has a PhD in pharmaceutics with a minor in physical chemistry from the University of Missouri. Contact him at ayaman@biopharmadvice.com.

• 
  www.devicelink.com/mddi/archive/09/07/002.html - [Cached Version]
  Published on: 7/2/2009    Last Visited: 7/2/2009  

  You can measure the growth of drug-eluting stents, for example," says Charlie Whelan, director of Frost & Sullivan's healthcare and life sciences consulting practice. With the convergence of healthcare IT, diagnostic imaging, clinical diagnostics, medical devices, pharmaceuticals, and biotech, they're all beginning to overlap with each other, says Whelan.

• 
  www.fortherecordmag.com/archives/052509p20.shtml - [Cached Version]
  Published on: 5/25/2009    Last Visited: 9/9/2009  

  Charlie Whelan, director of consulting in the Healthcare & Life Sciences Group at Frost & Sullivan, believes decision support systems are an important component of where HIT needs to go.
  
  While CDSS will achieve their full potential as part of the EMR, most of today's systems are not yet linked, says Whelan, who adds that most hospitals' EMRs are not sophisticated enough to handle that assignment.
  
  Whelan views the current market for CDSS tools primarily as those delivered via handheld technology, such as Palm Pilots and iPhones. "The doctor has a PDA, the information is updated, and he can use a checklist of questions and other content to support patient care," he says.
  
  Whelan says CDSS technology is more popular among younger physicians because they are more tech savvy and don't trust their judgment as much as their more experienced counterparts. "There is a huge market with medical students; often medical schools will issue PDAs to their students to use as a learning tool," he says.
  
  The information, while not patient specific, is presented in an encyclopedia-like format that offers a checklist to help with a diagnosis. The ability to connect the decision tools to the EMR gives the technology additional juice. "Where the value kicks in is when the patient information is tied to the clinical support," says Whelan, adding that hospitals should develop facility-specific standards in addition to the universally accepted standards such as drug-drug interactions.
  
  Whelan says there is a trend toward more hospitals creating guidelines that are germane to their facility. Also, healthcare societies have begun developing standards in conjunction with companies that develop CDSS technology. Putting all these pieces together and delivering them in a "digestible" format that is physician friendly will be the key to this technology's success, he adds.
  
  Barriers to Implementation In today's healthcare environment, where doctors are forced to do more in less time, CDSS technology can be viewed as more of an obstacle than a tool that will increase efficiencies. Simply put, many physicians do not want to add another step in the patient care process. However, "Order sets reduce time and allow for decision making based on the best clinical evidence they have today from inside and outside the facility," Whelan says.
  ...
  Teich says CDSS have a track record of success, while Whelan is anxious to see how the "conflict" between man and machine plays out.
  ...
  I think we'll continue to see significant growth in this area," Whelan says.

• 
  www.oandpbiznews.com/200702b/fs1.asp - [Cached Version]
  Published on: 2/15/2007    Last Visited: 5/29/2009  

  An active but aging population is the leading cause for a steady increase in the orthosis market, Frost & Sullivan reveals in their study, “U.S. Orthopedic Braces and Supports Markets.” This forecast was based on interviews with competitors in the marketplace as well as various health care professionals including orthopedic surgeons, physical therapists, athletic trainers, orthotists and prosthetists, Charlie Whelan, senior industry analyst for Frost and Sullivan, said.
  ...
  “The orthopedic brace and support industry as a whole is not a high growth market,” Whelan said. “It has grown 2% to 3% a year but it is a more than a billion dollar marketplace.”
  
  Unlike other markets that consist of one or two different products that bring in billions of dollars each year, the orthosis and support market is varied and includes different types of products that all fall under the same umbrella.
  
  “The marketplace that a lot of people are looking at is osteoarthritis knee braces which is an under-penetrated marketplace and has been growing by leaps and bounds in recent years,” Whelan told
  ...
  “I think O&P professionals are rightly concerned with the shift to off-the-shelf braces,” Whelan said.
  
  This shift, along with the implementation of stock-and-bill programs, allows physicians to address their patients’ orthotic and support needs without referring them to an O&P professional to be fitted for a custom orthosis, Whelan explained.
  
  What lies beyond 2012?
  
  Climbing Billion Dollar Orthosis and Support Market It is difficult to look beyond the next 5 years but Whelan can say that orthoses and supports are not going away.
  
  “There are certain issues that are biomechanical in nature which require some kind of orthotic and prosthetic or brace or support,” he said.
  
  Whelan said there are some key areas of the market to watch. The ankle marketplace is one of them taking into account recent enhancements to orthosis and support designs in an effort to more aggressively treat ankle injuries. Also, in the course of collecting data for the study, Whelan noted there was a lot of talk among industry competitors about prophylactic use of orthoses to be implemented as protection for otherwise healthy areas of the body.
  
  The possibility of creating more specialized postoperative orthoses and supports for specific high-volume cases was another topic of conversation.
  
  “For example, there have been a lot of surgical advances in the last decade or so with respect to shoulder surgery,” Whelan said.
  ...
  Whelan noted a shift toward battery-powered versions of those devices which indicates that the marketplace for non-powered disposable pumps is going to be on the decline during the next couple of years as more of these products shift to battery operation.
  ...
  “Depending on where you sit, that can be a good thing or a bad thing,” Whelan said. “From a good perspective, it means greater synergies.”
  
  Combining the financial and technological assets of two or more successful companies has the potential to effect the consumer population greatly, he said.
  
  “On the other side, these mergers may contribute to a more price driven marketplace,” Whelan said.
  
  Another worry is that new innovation may decrease due to the lack of competition. Less competition in the marketplace could cause the motivation to innovate to drop drastically.
  
  Whelan said the makeup of the orthosis and support marketplace is 80% low innovation product and 20% specialized, niche, high growth, high margin product.

Page:  1 2 3 4